DSIP
Delta sleep-inducing peptide
Research overview
A nonapeptide studied in models of sleep architecture and delta-wave regulation.
Descriptions reference published research areas for laboratory context only and are not claims of efficacy, safety, or intended use in humans or animals.
- Price
- $105 CAD
- Purity
- ≥98.5% (HPLC)
- Presentation
- 5 mg lyophilized vial
Order / inquire about DSIP
Email our research desk for availability, batch Certificates of Analysis, and account setup. We respond to verified research inquiries from Canada only.
Verified Canadian research inquiries only · 18+
For laboratory research use only — not for human or veterinary use
DSIP is a chemical reference material sold strictly for in-vitro laboratory research by qualified professionals. It is not a drug, food, cosmetic, or natural health product; it has not been evaluated or approved by Health Canada; and it must never be ingested, injected, or applied to humans or animals. Sold in Canada only, to purchasers 18+. See our Research Use Policy.
Research encyclopedia
Everything the literature has studied.
For laboratory research use only — not for human or veterinary use. The content below summarizes published research context only. It is not medical advice, makes no therapeutic claims, and describes no intended use in humans or animals. These materials have not been evaluated or approved by Health Canada.
What it is
DSIP (delta sleep-inducing peptide) is a naturally occurring nonapeptide (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) associated with the induction of delta (slow-wave) EEG activity and neuroendocrine modulation. Its status as a genuine neurotransmitter/neurohormone remains under scientific debate—no specific receptor or gene has been definitively identified.
Mechanism of action
The exact mechanism remains unclear. Evidence suggests modulation of the HPA axis (reduction of cortisol/ACTH under stress), possible involvement of NMDA-receptor and glutamatergic signaling, GABAergic facilitation, and serotonergic modulation, plus effects on other neuroendocrine outputs (GH, thyroid hormones, melatonin). No single validated receptor mediates these effects.
Research areas
- Sleep regulation and architecture (delta EEG activity)
- Modulation of stress and the HPA axis
- Withdrawal syndromes (alcohol and opioids)
- Chronic pain (analgesia models)
Studied effects in research models
- Reduction of cortisol/corticosterone in stress models
- Reported modulation of delta EEG activity (inconsistent across labs)
- Symptomatic relief in a clinical opioid/alcohol-withdrawal study (67 patients)
- Neuroendocrine modulation (GH, thyroid, melatonin) in some reports
Effects listed describe observations reported in laboratory or animal research models only — not outcomes claimed for humans or animals.
Biomarkers tracked in related research
Discovery & background
Isolated from the cerebral venous blood of rabbits and characterized in 1977 by Guido Schoenenberger and Marcel Monnier in Switzerland, following intraventricular/dialysate infusion experiments that increased delta EEG activity in recipient animals. Despite decades of study, its physiological role, receptor, and encoding gene remain unresolved, and it is often described as an unresolved neuropeptide riddle.
Considerations & limitations
Research-use-only reference material; not approved by Health Canada, the FDA, or the EMA. Most research is in animals; human trials are scarce, heterogeneous, and often unreplicated, and no specific receptor or gene has been identified—undermining the proposed sleep-inducing mechanism itself. Sleep results are inconsistent. No safety data in pregnancy, lactation, or pediatrics; caution in endocrine or stress-axis disorders given possible hormonal modulation.
References
- [1]Schoenenberger & Monnier, 1977 (DSIP characterization) — Proc Natl Acad Sci USA; 74:1282-1286; PMID: 265569
- [2]Graf & Kastin, 1986 (DSIP review) — Neurosci Biobehav Rev; 10:83-93; PMID: 3517656
- [3]Kovalzon & Strekalova, 2006 (DSIP delta-sleep debate) — Neurosci Behav Physiol; 36:159-166; PMID: 16385402